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The emergence of the COVID-19 virus and the subsequent pandemic have driven a
great deal of research activity. The effects of COVID-19 are caused by the severe
respiratory syndrome coronavirus 2 (SARS-CoV-2) and it is the underlying actions of
SARs-CoV-2 virions on the endothelial glycocalyx that we consider here. One of the key
factors in COVID-19 infection is its almost unique age-related profile, with a doubling in
mortality every 10 years after the age of 50. The endothelial glycocalyx layer is essential
in maintaining normal fluid homeostasis, but is fragile and prone to pathophysiological
damage. It is physiologically significant in capillary microcirculation and in fluid distribution
to the tissues. Human serum albumin (HSA), the most abundant protein in plasma, is
created in the liver which also maintains its concentration, but this reduces by 10–15%
after 50 years of age. HSA transports hormones, free fatty acids and maintains oncotic
pressure, but SARS-CoV-2 virions bind competitively to HSA diminishing its normal
transport function. Furthermore, hypoalbuminemia is frequently observed in patients with
such conditions as diabetes, hypertension, and chronic heart failure, i.e., those most
vulnerable to SARS-CoV-2 infection. Hypoalbuminemia, coagulopathy, and vascular
disease have been linked in COVID-19 and have been shown to predict outcome
independent of age and morbidity. Hypoalbuminemia is also known factor in sepsis and
Acute respiratory distress syndrome (ARDS) occurs when fluids build-up in the alveoli
and it is associated with sepsis, whose mechanism is systemic, being associated with
the fluid and logistic mechanisms of the circulation. Glycocalyx damage is associated
with changes plasma protein concentration, particularly HSA and blockage of albumin
transport can produce the systemic symptoms seen in SARS-CoV-2 infection and sepsis.
We therefore conclude that albumin binding to SARS-CoV-2 virions may inhibit the
formation of the endothelial glycocalyx by inhibition of albumin transport binding sites.
We postulate that albumin therapy to replace bound albumin might alleviate some of
the symptoms leading to sepsis and that clinical trials to test this postulation should be
initiated as a matter of urgency.
Keywords: human serum albumin, septic shock, coronavirus, endothelial glycocalyx layer, acute respiratory
distress syndrome, albumin therapy
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INTRODUCTION
The COVID-19 pandemic has renewed interest in emergent
pathogens as a major threat for human health. To date many
millions have been infected and hundreds of thousands or greater
mortality is expected. Quantitative approaches to the current
outbreak are urgently needed to tackle this severe disease.
Coronaviruses are found in many different species of animals
(e.g., bats and dromedaries) and can become infectious in
humans. Typical spread is by droplets from coughing or sneezing,
aerosol, or direct contamination for example through stools. The
active virion SARS-CoV survives well and can survive without
denaturing for up to 2 weeks in stools after infection. Coronavirus
infections are not new, the Severe Acute Respiratory Syndrome
(SARS-CoV-2), reported in Asia in February 2003 resulted in
almost 9,000 cases with a case-fatality rate of 10%. In 2012,
(MERS-CoV) infected more than 2,500 people, killing over 800.
Epidemiological models help policy makers to take decisions.
Social distancing has helped mitigate the spread of the epidemic
and lockdown of successive geopolitical zones has sequentially
reduced both spread and mortality of the disease. Such methods
could eradicate the virus but necessitate global co-operation, as
does vaccination.
There are many epidemiological unknowns with COVID-19.
Infection andmortality rates are still being collated from different
sources with varying degrees of accuracy and reliability. Whilst
much is uncertain in COVID-19 pandemic, aspects of the disease
are well documented such as age related mortality effectively
doubling for each 10 years after 50, obesity (1) and the effects on
black, Asian and minority ethnic (BAME) individuals (2) which
may be unrelated to direct environmental factors and for which
there is some evidence of a link to melatonin (3).
One of the difficulties with research into the human body is
the transposition of these presentations to cellular physiological
and molecular causative events. Of greater mathematical
complication is the necessity to understand how within a whole-
body cellular infection caused by molecular events lead to
systemic injury and death.
In this paper our attention is not in in predicting who dies,
but in using this data to find out what corporeal elements
have been systemically disturbed and which can account for the
differences in mortality across aging, sex and obesity among
others. The answer has to be found at the molecular level and
as already suggested in the logistical supply of trophic materials
to allow the virus to multiply safely without precipitating cell
death before the inflection point where the speed of antibody
production to remove the virus is enough not to precipitate
sepsis. Pathology of systemic sepsis is associated with death in
COVID-19 patients (4).
INFECTION
Our understanding of the infection at the cellular level is still poor
but we can make assumptions based upon peer-reviewed studies
of other infections. Some direct experimentation has already
taken place, for example the effects on age from experiments
on macaques (5). However, presentation of death related factors
and statistical evaluation at the population level of infection and
subsequent death rates has resulted in some factors of universal
agreement across many countries. A discussion of the exact
nature and precision of these evaluations is beyond the scope
of this paper, but enough trends from statistical evaluation have
been corroborated that allow us to understand both the infection
of single individuals and the passage of the COVID-19 virions as
they infect single cells and multiply leading to systemic infection
and sometimes death.
There have been many suggested criteria examined for
prognosis of COVID-19 and these epidemiological markers
have been used to selectively profile and isolate members of
communities in order to offer protection. The most important
of these is the almost unique presentation of age profile, which in
epidemiological terms occurs after 50 years of age with a doubling
in mortality every 10-years thereafter. Unlike during the 1918
influenza outbreak where prognosis for both the young and the
old was one of the major factors of mortality n COVID-19 the
majority of deaths are in the over 50s. This difference is crucial
in defining the cellular and molecular actions of the virus in
infection. Similarly, the high death rates for obese patients and
BAME communities may give indications of the mechanism of
the virus action as well as the need for protection of minorities.
Symptoms of the disease are also indicators for the metabolic
distribution of the virions around the body at different stages
of the disease. Finally, it must be remembered that at all stages,
death is usually presaged by systemic spread of the disease
leading to sepsis, which is discussed in detail below. If we are
to successfully model the cellular and subcellular of COVID-
19, then all forms of systemic stress, such as the multi system
inflammatory syndrome (MSIS) Kawasaki type illnesses seen in
young children (6) and multi organ failure and sepsis, must
be identified.
INFECTION VECTOR
Primary presentation of COVID-19 can include shortness of
breath, coughing, loss of smell and taste, and stomach pains,
but may include many other symptoms. At the cellular level
there are many common events that can be quantified. The
infection vector is usually respiratory. SARS-CoV-2 binds to
the common angiotensin-converting enzyme 2 (ACE2) (7) cell-
surface receptor (8, 9). The virus infects cells using the ACE
2 receptor a precursor in the renin-angiotensin system to
angiotensin II a vasoconstrictor. ACE 2 is present in many cell
membranes of also all organs and serves numerous purposes
within the cell. Infection usually occurs through the lungs, but
the ACE 2 receptors are also represented throughout the intestine
and nasal epithelia and can also take these routes (5).
ACE2 is prevalent throughout the body. Prevalence of ACE2
makes tissues vulnerable to infection, as the virus requires that
receptor be present to enter a cell (7, 9, 10). Virion RNA
is then released into the cell where it mimics the cells own
messenger-RNA (mRNA). SARS-CoV-2 RNA impersonates the
cell’s own mRNA instructing the cell to produce the relevant
proteins to construct new virions which are then released from
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the cell. Antiviral drugs act against this mechanism. The ability
of antiviral drugs to slow virion multiplication is an important
element against the initial infection. However, deaths ascribed
are not due to the SARS-CoV-2 virion but to the consequent
disruption to cellular components—this is evidenced by the
difference between old and young victims. In older individuals,
changing metabolism has rendered them vulnerable. The source
of this disruption may only partly be due to the virion itself.
In COVID-19, infection manifests in the alveoli of the upper
lungs. Oxygen crosses the alveoli into tiny capillaries that lie
beside the air sacs (11, 12). The oxygen is then carried to
the rest of the body by hemoglobin in the blood. COVID-
19 destroys this process causing oxygen debt, but this may be
a secondary symptom. White blood cells release inflammatory
molecules in response to abnormality in the cell leading to
inflammation and apoptosis (cell programmed death). This is
the underlying pathology of pneumonia, with its corresponding
symptoms: coughing; fever; and rapid, shallow respiration. Some
COVID-19 patients recover, sometimes with no more support
than oxygen. Others deteriorate, often quite suddenly, developing
a condition called acute respiratory distress syndrome (ARDS)
(13). Oxygen levels in their blood plummet and they struggle ever
harder to breathe (13, 14). On x-rays and computed tomography
scans, their lungs are riddled with white plaques resembling
ground glass. Commonly, these patients must be artificially
ventilated and their mortality is high. There is no evidence that
extracorporeal membrane oxygenation (ECMO) machines that
bypass the lungs ameliorate the systemic sepsis and mortality
rates of patients from those on a ventilator, probably because
the oxygen carrying capacity of the blood is severely attenuated
(14). Autopsies have shown that the alveoli were inundated
with fluid, eukaryotic material and dead lung tissue (11, 12).
Concurrent with this pathology organ failure renal, hepatic and
cardiovascular are precipitated by sepsis of the capillary network
(15). Subsequent prevalence of clotting, multiple organ failure
and all the symptoms of sepsis give a diagnosis of systemic septic
shock in almost all deaths.
Most individuals recover quickly from COVID-19 infection,
producing antibodies to the disease. However, it should be noted
that most patients who do not recover have already either begun
to produce antibodies (11) and weak immune system is not a
factor in their deaths, but a slow immune system can have fatal
consequences. Almost all infected individuals survive the first
infection of the virus. Virion levels rise to their maximum and
almost all patients produce antibodies. The antibody response is
therefore critical to recovery but does not necessarily preclude
mortality. Timing is critical between the infection and antibody
response and the vulnerabilities of an individual determine
their survival.
BACTERIAL VS. VIRAL INFECTION
The basic parameters of bacterial and viral infections differ.
Bacteria use their own cellular structures to multiply and
do not require the host cellular structures- they can use a
primordial pool of material, viruses are restricted to using the
host cells own structures to multiply and thus must retain the
structural integrity of the host to continue to multiply. Once
the cell is depleted of material capable of sustaining the ongoing
multiplication deficits will occur disturbing the inherent makeup
of cellular components rendering visible to the immune system.
For cellular structures to remain intact a constant stream of
trophic material must be provided to the cells. Unlike bacteria
that can survive and proliferate within a dead environment,
viruses like Sars-COVID-19 cannot. The early action of the virus
is thus not to damage its own environment and damage to the
cell is initially from molecular instability external to normal
metabolism and a consequence of cellular logistical inefficiency
to provide the requisite materials for the virus to continue its
replication. Although often overlooked the virus in early stages
of infection is more dependent upon its host than a bacterium. In
turn the mechanism of reproduction and subsequent depletion
is of is fundamentally important when considering the spread
and infection of COVID-19 virions within a body and systemic
release and functional damage and subsequent death. If the virion
is permitted to replicate where the logistics of cellular structural
integrity remains little change will come to the cell. Only when
the material for reproduction in terms of molecular quantities of
building materials ceases will the mRNA of the virion continue
to consume the cellular structure of the host cell. This in turn
may change the cellular membrane structure making it visible
to antibodies.
APOPTOSIS
The action of cytokine system (16, 17) is not to destroy cell in
response to an infection but as a result of cellular incapacity to
operate within normal limits as to its function (18). COVID-
19 replication depletes the infected cell of material, and usurps
its mechanisms. The change from normal activity in turn
changes the biochemical nature of reactions at the molecular
level starving necessary components necessary to maintain
homeostatic integrity. Any action considered normal for the cell
does not therefore produce apoptosis, but cytokine release to
instigate apoptosis is a result of major cellular damage.
SPEED OF INFECTION AND FALSE
IMMUNITY
Viral and host factors play important roles in the course of
infection. Critical to life expectancy and prognosis is the speed
of infection and subsequent immunity. The development of
immunity is critical in the systemic spread of COVID-19 and
some assumptions must be questioned as to their scientific
acceptability. Immunity can either be from vaccination or from
previous exposure. In both cases the body retains antibodies
that deteriorate over time (15). Viruses can quickly mutate (19).
A COVID-19 vaccination may be ineffective against any new
mutation (20). In addition, vaccination against a specific virus
will only work effectively while enough antibodies exist in the
body with the ability to multiply at a fast enough rate to negate
the disease (20). This will decrease with time and immunity
will only occur if there are enough antibodies to be replicated
Frontiers in Cardiovascular Medicine | www.frontiersin.org 3 September 2020 | Volume 7 | Article 153
Johnson et al. HSA Role in Covid-19 Infection
fast enough to overcome the multiplication of virions before
they reach the point where apotosis and sepsis takes place. The
rules therefore are dependent upon how much each individual
is immunosuppressed due to their inherent vulnerabilities and
the infection rate. Antibody production does not occur instantly
and individuals with immunity are therefore capable of spreading
the disease during this process. Thus, all individuals, whether
immunized or not, whether showing symptoms or not, become
infectious as the immunity commences and this infection
continues until antibodies have destroyed every virion present
in the body. All individuals therefore are inherent carriers and
spreaders of the disease, whether they have immunity or not,
by either vaccination or previous infection. As yet, there is no
evidence that either vaccination or prior exposure prevents a
second exposure from being infectious during the time between
infection and destruction of the virus.
In a bacterial infection bacteria divide doubling according to
time and medium and occurs exponentially until resources for
division are expended. Viruses by contrast do not require division
to replicate but use the mRNA and the sarcoplasmic reticulum
of the host cell. A single virion may infect a cell and its RNA
produce many virion copies unrestricted by the requirement to
divide. Virus replication may therefore occur faster than simple
exponential division with a single virion multiplying many times
up to the point where material for replication is expended. A
single virion infecting a cell is therefore sufficient to replicate
until the materials for its own division have been expended. Each
cell infection also has a critical limit of replication caused by
depletion of nutrients which lead to cell death.
ACUTE RESPIRATORY DISTRESS
SYNDROME AND SEPSIS
ARDS occurs when fluid builds up in the alveoli and is
associated with sepsis (21). Sepsis is life-threatening condition
due to a dysregulated host response to infection, which is time-
dependent and associated with unacceptably high mortality (13,
22). Mortality remains higher than 25–30% and even higher
when shock is present. No effective specific anti-sepsis treatments
exist (23).
Sepsis results when an infection triggers a localized
inflammatory reaction that causes systemic symptoms of fever or
hypothermia, tachycardia, tachypnoea, and either leucocytosis
or leukopenia, i.e. the systemic inflammatory response syndrome
(24). Severe sepsis is defined by dysfunction of one of the major
organ systems. The inflammatory reaction is mediated by the
release of cytokines. Cytokines activate the extrinsic coagulation
cascade and inhibit fibrinolysis. According to Assiri et al.
(25), higher concentrations of the pro-inflammatory cytokine
interleukin-6 (26) and the fibrin degeneration product D-dimer
(27) were strongly associated with in-hospital mortality in
COVID-19. These overlapping processes result in microvascular
thrombosis. Thrombosis is one potential factor producing
organ dysfunction. Management of patients with sepsis relies
mainly on early recognition and correct therapeutic measures.
Treatments involve antibiotics resuscitation with intravenous
fluids and drugs acting upon targets that are components of
the inflammatory response, cytokines such as tumor necrosis
factor (TNF), interleukin 1, interleukin 6, or platelet activating
factor, or components of the coagulation cascade or vasoactive
molecules (28).
The mechanism of sepsis is systemic, being intrinsic to the
fluid and logistic mechanisms of circulation, with symptoms
originating at the cellular level (29). This pathology manifests
in the epithelial cells separating tissues from the external
environment and capillary leak syndrome (30). Epithelial cells
maintain structural integrity of tissues including the small
capillary vessels that surround the alveoli in the lungs and the
capillaries of all other organs. Epithelial cells are lined with a
gel-like surface of interconnected proteins call the endothelial
glycocalyx (31).
ENDOTHELIAL GLYCOCALYX LAYER (EGL)
The endothelial glycocalyx layer has an essential role in
maintaining the normal fluid homeostasis of the body (32), but
is fragile and can be damaged by a number of pathophysiological
conditions and interventions.
The physiology of the endothelial glycocalyx layer has been
shown to significantly affect the microcirculation reducing
fluidity in capillary flow. Recently the Starling principle of fluid
reabsorption and oncotic maintenance in the capillary network
has been shown to exist almost exclusively across this layer and
not as previously supposed across the capillary system. This
has produced the reformed Starling principle (31) that defines
fluid distributionmore accurately as occurring almost exclusively
though this layer. The EGL is therefore essential in maintaining
correct oncotic pressure in the capillary bed as well as influencing
the adsorption and reabsorption across the capillary membranes.
In fluid therapy where osmotic pressure changes, damage may
be done to this layer decreasing its thickness and altering its
fundamental structural integrity—this is well summarized by
Kundra (31). Thus, the EGL maintains the functional integrity
and mechanisms supporting not just the physical integrity of
the endothelial transport system but also its pathophysiology. In
(33) it was concluded that ‘Glycocalyx damage may be limited by
avoiding hypervolemia and hyperglycaemia and by maintaining
a physiological concentration of plasma protein, particularly
albumin’. Plasma transfusion has been effective protection of the
EGL (34) and has been implicated in preeclampsia (35). Albumin
has been proposed for therapeutic targeting of the EGL (36).
The main point is that under physiological conditions oncotic
pressure is maintained by human serum albumin HSA.
In septic shock damage to the EGL can also cause
inflammation of the vascular endothelium and maldistribution
of microvascular blood flow as well as the release of the damaging
free radical such as nitric oxide (37) which is normally involved in
regulation of vascular homeostasis (38), but uncontrolled release
is likely to add to tissue and erythrocyte damage, thus reducing
the oxygen carrying capacity of blood. The current literature on
serology in patients with COVID-19 have reported decreased
hemoglobin concentration in these individuals (39). They stated
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that coronavirus binds to hemoglobin and frees the iron ions,
leading to impairment in the oxygen delivery to the vital organs,
release of free radicals and thus elevation in stress, oxidative
load, hypoxia and finally heart attack or cardiac arrest may occur
(40, 41). There is further evidence for hemoglobin impairments,
such as elevated serum ferritin, erythrocyte sedimentation rate,
C-reactive protein, lactate dehydrogenase (40, 42). Underlying
all of this is damage to the EGL due to modulation of serum
albumin by the SARS-CoV-2 virion-albumin binding site as
explained below.
HUMAN SERUM ALBUMIN
Serum albumin (43) functions as a significant regulator of plasma
oncotic pressure and a transporter of ligands (44–46). It has
a half-life in the body of about 20 days and decreases by 10–
15% after 50 years of age (47). Importantly 80% of free albumin
is contained within the interstitial spaces where it must be
assumed to perform the same transport function. Albumin is
created in the liver which maintains its concentration, but this
reduces after 50 years of age (47). In clinical medicine, serum
albumin can be measured via standard serum laboratory testing
that measures both free and bound albumin. Free fatty Acids
(FFA), melatonin (2, 48–50) and the SARS-CoV-2 virions are
transported bound to albumin as are glycolates. Studies on
drug interactions confirm both competitive and non-competitive
binding (49, 51–54). The role of albumin is well accepted
in regulation of hormones (55–57). Research on albumin has
provided new insights such as the characterization of the
pleiotropic effects of albumin (58). Conformational change to
albumin can affect binding of viruses (59). The exact binding
sites and therefore the interactions between protein FFA are
unknown however the basic mechanism of competitive and
non-competitive binding sites have been described. Albumin
binds, mostly non-specifically, with each ligand having different
affinity for competing sites (60). Glycosylated albumin has long
been known to affect platelet aggregation (61) a factor of
clotting. Hypoalbuminemia is frequently observed in patients
with conditions like diabetes, hypertension and chronic heart
failure, and who are statistically most vulnerable to SARS-
CoV-2 infection. According to Huang et al. (62) low albumin
levels are seen in almost 81% of non -surviving COVID-19
patients and a clinical trial to examine the effects of intravenous
infusion of albumin to COVID-19 patients with respiratory
insufficiency has recently been registered in India (63). Recently
hypoalbuminemia, coagulopathy and vascular disease have been
linked in COVID-19 (64) and has been shown to predict outcome
independent of age and morbidity (65). Hypoalbuminemia is a
known factor in sepsis and ARDS (46, 66–68).
Albumin bonds to ligands by a reversible process where the
equilibrium between bound and unbound depends upon the
relative concentrations and depends upon ligand. All ligands
capable of binding including proteins fatty acids and indeed
the SARS-CoV-2 virus are bound in competition for sites to
bind upon the albumin molecule as other viruses (45). There
are both specific and non-specific areas of binding on an
FIGURE 1 | Proposed equilibrium of binding for albumin with FFA determined
by lipid cells. Reversible albumin binding of both EGL proteins and FFA
determines the concentrations non bound in plasma. If enough SARS-CoV-2
virions bind to albumin they will reduce the concentration of glycocalyx and
thus deplete the endothelial glycocalyx layer. Similarly, excess FFA due to
obesity causes reduction in the EDL or other ligands bound to albumin.
albumin molecule representing different affinities for different
ligands (60, 69, 70).
BINDING OF SARS-CoV-2 TO ALBUMIN
The nature of the SARS-CoV-2 virion-albumin binding site is
unknown, but some permanent binding cannot be discounted as
proposed in Figure 1. At the cellular level the SARS-CoV-2 virus
enters the body and uses the cells own apparatus to replicate itself.
One single virion can use the mechanisms inherently available to
replicate itself in a single cell, and there is no evidence to suggest
this process harms the cell. Damage to the cell can only be caused
by instability of the cellular mechanisms by depletion of nutrients
necessary for replication of the virus and the wellbeing of the cell.
Depletion is most likely to occur by expenditure within the cell
due to repeated virion manufacture and ejection. The result is an
unstable cell vulnerable to apoptosis. The maintenance of the cell
is the critical factor and is determined by the delivery of nutrients
and the rate they are used. The levels of nutrients supplied by the
blood determine this equilibrium.
Spread can be local where one cell releases directly to another
adjacent cell or through the extracellular fluid surrounding the
tissues leading to systemic release. Initially virions released from
a site infectionmay remain localized. Once they are released, they
travel in the blood and lymph bound to albumin.
The immunity conferred on the young must be because of
the difference in the systemic environment. Obesity results in a
rise in the plasma free fatty acids that are bound to albumin thus
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reducing the unbound portion (71). In COVID-19 patients, the
level of serum albumin is decreased and the body requires more
serum albumin (42). In cases of influenza and other respiratory
viruses supplementation with bovine serum albumin was used
as a transport medium in a community-wide surveillance of
febrile respiratory disease for influenza viruses in order to
attenuate the enhanced production of reactive oxygen species
such as hydroxyl radicals by neutrophils during an influenza viral
infection (72, 73).
CONCLUSION
Unlike influenza where both young and old were affected SARS-
CoV-2mortality increases over 50 years of age. There are very few
directly measurable systemic events that change during aging that
could be a culprit for death occurring among the over 50’s and
obese. The reduction of the overall concentration of albumin in
the extracellular body fluids is the most likely source of limitation
for the transport of substances around the body transporting
up to 80% substances. Here we suggest that the albumin
complex is inherently the maintainer of homeostatic regulation
of essential cellular nutrients as well as oncotic pressure. Our
model suggests that albumin transport plays a direct role in
the stasis of nutrients that supply the cellular structures that
regulate the thickness of the EGL. This provides a direct link
from the behavior of cellular SARS-CoV-2 infection, in this case
to the destruction of this layer leading to sepsis and general
septic shock.
On infection the initial response of infected tissues is to
accommodate the virus. This is accompanied by a release of
virions into the systemic system where they are bound in
equilibrium with Human serum albumin. As infection continues
and viral particles expand the ratio between bound and unbound
virion-albumin increases until a crisis point is reached. The
bound albumin-virion displaces the ligands present on albumin
by corresponding amounts. Reduced nutrients provoke cell stress
and then apoptosis. Tolerance to the virus thus depends upon,
amount of free-albumin. As infection continues the ability of
albumin to transport nutrients depends upon the extent of free
albumin. Albumin moderates binding the levels of nutrients
in the blood. Release of virions into the bloodstream therefore
prevents albumin from transporting nutrients into the cells.
We conclude therefore that albumin therapy to replace bound
albumin, or strategic addition of HSA to increase the overall
concentration in the fluid components of delivery (plasma and
interstitial fluid, etc.) might alleviate some of the symptoms
leading to sepsis (23, 74). A rise to average albumin levels we
predict could alleviate systemic sepsis and prevent death (23, 74).
Fluid therapy bundles are available (75–77) containing albumin.
However, these are of very low percentages 4% which may
become quickly bound and a more long-term sustained approach
would be preferable (78).
Fluid therapy is especially important in many surgical
situations and this type of physiological intervention whilst not
commercially attractive is none the less extremely valid and has
a vast history of solid physiological and biochemical research
evidence to support it. This is an area of research that is
important and apparent in every operation where fluid is given
has historically been neglected.
By changing the albumin-bound to albumin-free systemic
stress can be reduced with the hope that more lives are saved.
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